z-logo
Premium
Staphylococcus aureus triggers nitric oxide production in human upper airway epithelium
Author(s) -
Carey Ryan M.,
Workman Alan D.,
Chen Bei,
Adappa Nithin D.,
Palmer James N.,
Kennedy David W.,
Lee Robert J.,
Cohen Noam A.
Publication year - 2015
Publication title -
international forum of allergy and rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.503
H-Index - 46
eISSN - 2042-6984
pISSN - 2042-6976
DOI - 10.1002/alr.21568
Subject(s) - medicine , staphylococcus aureus , nitric oxide , airway , epithelium , microbiology and biotechnology , respiratory epithelium , pathology , bacteria , anesthesia , genetics , biology
Background Nitric oxide (NO) is an important antibacterial defense molecule produced by upper airway (sinonasal) epithelial cells. We previously showed that a bitter taste receptor expressed in airway epithelium detects quorum‐sensing molecules secreted by Gram‐negative bacteria and subsequently triggers bactericidal NO production. We hypothesized that the upper airway epithelium may also be able to detect the Gram‐positive aerobe Staphylococcus aureus and mount an NO response. Methods Human sinonasal air‐liquid interface (ALI) cultures were treated with methicillin‐resistant S. aureus (MRSA)‐conditioned medium (CM), and NO production was measured using fluorescence imaging. Inhibitors of bitter taste receptor signaling were used to pharmacologically determine if this pathway was involved in the production of NO. Results A low‐molecular‐weight, heat, and protease‐stabile product found in MRSA CM induced differential, NO synthase (NOS)‐mediated NO production. This response varied markedly between individual patients. The MRSA‐stimulated NO production was not dependent on 2 important components of bitter taste signaling: phospholipase C isoform β‐2 or the transient receptor potential melastatin isoform 5 (TRPM5) ion channel. Conclusion This study shows that a S. aureus product elicits an NO‐mediated innate defense response in human upper airway epithelium. The active bacterial product is likely a small, nonpeptide molecule that triggers a pathway independent of bitter taste receptors. Patient variation in the NO response to MRSA product(s), potentially due to genetic differences, might play a role in pathophysiology of Gram‐positive upper respiratory infections and/or pathogenesis of chronic rhinosinusitis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here